Morgan Stanley China
Overview
Morgan Stanley China represents the Chinese operations of the global financial services firm, providing investment banking, securities, asset management, and private equity services. Its private equity investment activities are primarily conducted through Morgan Stanley Private Equity Asia (MSPEA), which focuses on privately negotiated minority investments and control buyouts in growth-oriented companies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Beijing Biosis Healing Biological Technology | Jul 2023 | Series D | Co-investor |
| Kaadas Group | Mar 2022 | Series C | Co-investor |
| Jana Small Finance Bank | Sep 2017 | Private Equity | Co-investor |
| KNX Human Resource Solutions | May 2017 | Series B | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Morgan Stanley China based?
Morgan Stanley China is headquartered in Shanghai, China.
When was Morgan Stanley China founded?
Morgan Stanley China was founded in 1994.
How many portfolio companies does Morgan Stanley China have?
Morgan Stanley China has 4 portfolio companies in Caplight's dataset.
What are some companies in Morgan Stanley China's portfolio?
Recent investments visible on Caplight include Beijing Biosis Healing Biological Technology, Kaadas Group, Jana Small Finance Bank, KNX Human Resource Solutions, Jana Small Finance Bank.
What was Morgan Stanley China's most recent investment?
Morgan Stanley China's most recent investment on Caplight was in Beijing Biosis Healing Biological Technology in 2023.
What sectors does Morgan Stanley China focus on?
Morgan Stanley China focuses on FinTech, Healthcare & Life Sciences, Consumer & Commerce, Enterprise Software, Real Estate & PropTech, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech.
What company stages does Morgan Stanley China focus on?
Stage focus information for Morgan Stanley China is not publicly available.